U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...